LT1988823T - Lėtas intraventrikuliarinis pateikimas - Google Patents
Lėtas intraventrikuliarinis pateikimasInfo
- Publication number
- LT1988823T LT1988823T LTEP07750236.7T LT07750236T LT1988823T LT 1988823 T LT1988823 T LT 1988823T LT 07750236 T LT07750236 T LT 07750236T LT 1988823 T LT1988823 T LT 1988823T
- Authority
- LT
- Lithuania
- Prior art keywords
- intraventricular delivery
- slow
- slow intraventricular
- delivery
- intraventricular
- Prior art date
Links
- 238000007914 intraventricular administration Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77145106P | 2006-02-09 | 2006-02-09 | |
| PCT/US2007/003382 WO2007095056A2 (en) | 2006-02-09 | 2007-02-08 | Slow intraventricular delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT1988823T true LT1988823T (lt) | 2018-12-10 |
Family
ID=38372004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP07750236.7T LT1988823T (lt) | 2006-02-09 | 2007-02-08 | Lėtas intraventrikuliarinis pateikimas |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090123451A1 (https=) |
| EP (2) | EP1988823B1 (https=) |
| JP (4) | JP2009526066A (https=) |
| CN (1) | CN101404927A (https=) |
| AR (1) | AR059372A1 (https=) |
| BR (1) | BRPI0707900A2 (https=) |
| CA (2) | CA3168881C (https=) |
| CY (1) | CY1121822T1 (https=) |
| DK (1) | DK1988823T3 (https=) |
| ES (2) | ES3054134T3 (https=) |
| HU (1) | HUE040490T2 (https=) |
| IL (2) | IL193242A (https=) |
| LT (1) | LT1988823T (https=) |
| MX (4) | MX358492B (https=) |
| PL (1) | PL1988823T3 (https=) |
| PT (1) | PT1988823T (https=) |
| RU (1) | RU2452368C2 (https=) |
| SI (1) | SI1988823T1 (https=) |
| WO (1) | WO2007095056A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| HUE040490T2 (hu) | 2006-02-09 | 2019-03-28 | Genzyme Corp | Lassú intraventrikuláris szállítás |
| US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| ES2635726T3 (es) | 2007-06-06 | 2017-10-04 | Genzyme Corporation | Terapia génica para enfermedades de almacenamiento lisosómico |
| EP2167071B1 (en) * | 2007-06-13 | 2020-03-18 | Wayne State University Board Of Governors | A baclofen solution for low-volume therapeutic delivery |
| JP5903045B2 (ja) | 2009-07-31 | 2016-04-13 | パックスバックス， インコーポレイテッド | アデノウイルスに基づくベクター |
| SI3998078T1 (sl) | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| PT3103469T (pt) | 2010-06-25 | 2021-03-04 | Shire Human Genetic Therapies | Administração de agentes terapêuticos no snc |
| KR20150020250A (ko) | 2012-06-19 | 2015-02-25 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 당뇨병을 치료하기 위한 조성물 및 방법 |
| CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| KR102883778B1 (ko) | 2017-09-22 | 2025-11-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8303626D0 (sv) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| WO1995005864A1 (en) * | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
| CA2189067A1 (en) | 1994-04-28 | 1995-11-09 | Gary J. Nabel | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line |
| AU5551996A (en) | 1995-04-17 | 1996-11-07 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997025446A1 (en) | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
| US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
| MX340738B (es) | 1996-09-13 | 2016-07-22 | Shire Human Genetic Therapies | Terapia para deficiencia de a-galactosidasa a. |
| US7033598B2 (en) * | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
| US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
| US6702945B2 (en) | 2000-12-28 | 2004-03-09 | Exxonmobil Research And Engineering Company | Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions |
| US6689756B2 (en) * | 2001-03-02 | 2004-02-10 | Integra Lifesciences Corporation | Treatment of neurological disease |
| US20030163181A1 (en) * | 2001-12-07 | 2003-08-28 | Neuron Therapeutics, Inc. | Protection of neurological tissue by direct CNS perfusion cooling |
| EP1575562B1 (en) * | 2002-11-26 | 2016-10-05 | Seacoast Neurosciene, Inc. | Buoyant polymer particles delivering therapeutic agents |
| RU2253486C2 (ru) * | 2003-03-03 | 2005-06-10 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ химиотерапии опухолей центральной нервной системы |
| US20050102708A1 (en) * | 2003-03-12 | 2005-05-12 | Laurent Lecanu | Animal model simulating neurologic disease |
| US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| EP1638605B1 (en) * | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| EP1730183A2 (en) | 2004-01-27 | 2006-12-13 | Compugen USA, Inc. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| WO2005095955A1 (en) * | 2004-03-31 | 2005-10-13 | Children, Youth And Women's Health Service | Screening for lysosomal storage disease status |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| AR059088A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una proteina para esclerosis lateral amiotrofica |
| HUE040490T2 (hu) * | 2006-02-09 | 2019-03-28 | Genzyme Corp | Lassú intraventrikuláris szállítás |
| ES2635726T3 (es) | 2007-06-06 | 2017-10-04 | Genzyme Corporation | Terapia génica para enfermedades de almacenamiento lisosómico |
-
2007
- 2007-02-08 HU HUE07750236A patent/HUE040490T2/hu unknown
- 2007-02-08 ES ES18188582T patent/ES3054134T3/es active Active
- 2007-02-08 CN CNA2007800098972A patent/CN101404927A/zh active Pending
- 2007-02-08 RU RU2008136196/14A patent/RU2452368C2/ru not_active IP Right Cessation
- 2007-02-08 BR BRPI0707900-1A patent/BRPI0707900A2/pt not_active IP Right Cessation
- 2007-02-08 PL PL07750236T patent/PL1988823T3/pl unknown
- 2007-02-08 PT PT07750236T patent/PT1988823T/pt unknown
- 2007-02-08 MX MX2008010125A patent/MX358492B/es active IP Right Grant
- 2007-02-08 CA CA3168881A patent/CA3168881C/en active Active
- 2007-02-08 LT LTEP07750236.7T patent/LT1988823T/lt unknown
- 2007-02-08 DK DK07750236.7T patent/DK1988823T3/en active
- 2007-02-08 ES ES07750236T patent/ES2697502T3/es active Active
- 2007-02-08 CA CA2641359A patent/CA2641359C/en active Active
- 2007-02-08 AR ARP070100529A patent/AR059372A1/es not_active Application Discontinuation
- 2007-02-08 EP EP07750236.7A patent/EP1988823B1/en active Active
- 2007-02-08 SI SI200732069T patent/SI1988823T1/sl unknown
- 2007-02-08 JP JP2008554340A patent/JP2009526066A/ja active Pending
- 2007-02-08 MX MX2018015511A patent/MX392030B/es unknown
- 2007-02-08 EP EP18188582.3A patent/EP3459441B1/en active Active
- 2007-02-08 WO PCT/US2007/003382 patent/WO2007095056A2/en not_active Ceased
- 2007-02-08 MX MX2013013333A patent/MX361816B/es unknown
-
2008
- 2008-08-05 IL IL193242A patent/IL193242A/en not_active IP Right Cessation
- 2008-08-07 US US12/187,896 patent/US20090123451A1/en not_active Abandoned
- 2008-08-07 MX MX2022005303A patent/MX2022005303A/es unknown
-
2013
- 2013-08-21 JP JP2013171131A patent/JP6129685B2/ja active Active
-
2015
- 2015-09-25 JP JP2015188744A patent/JP6408970B2/ja active Active
-
2016
- 2016-10-25 IL IL248492A patent/IL248492A0/en unknown
-
2017
- 2017-08-08 JP JP2017152871A patent/JP6617125B2/ja active Active
-
2018
- 2018-11-15 CY CY20181101209T patent/CY1121822T1/el unknown
-
2019
- 2019-02-21 US US16/281,961 patent/US11253485B2/en active Active
-
2022
- 2022-01-10 US US17/572,330 patent/US20220370348A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1988823T3 (pl) | Powolne dostarczanie dokomorowe | |
| GB2456681B (en) | Pump | |
| GB2444395B (en) | Delivery devices | |
| GB2444394B (en) | Delivery devices | |
| AU309350S (en) | Pump | |
| AU310837S (en) | Pump | |
| AP2008004724A0 (en) | Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane | |
| GB0724548D0 (en) | Pump | |
| GB2435420B (en) | Delivery means | |
| GB2476731B (en) | Delivery devices | |
| GB0709390D0 (en) | Delivery means | |
| TWI320452B (en) | Pump | |
| GB2461433B (en) | Delivery devices | |
| EP2066903A4 (en) | PUMP | |
| GB0618385D0 (en) | Instant-action poker | |
| DE502007001126D1 (en) | Eiten | |
| GB0616952D0 (en) | Delivery | |
| GB0623680D0 (en) | Opposite straight | |
| AU4914P (en) | CalflatGL Calothamnus quadrifidus | |
| AU3514P (en) | ARCBENT Arctotis fastuosa | |
| GB0609986D0 (en) | Corcost 5e | |
| AP2007000231S (en) | Bycycle pump | |
| GB0619865D0 (en) | Pump | |
| PL379370A1 (pl) | Pompa | |
| GB0616772D0 (en) | Delivery/box |